Cellular Adhesion: Molecular Definition to Therapeutic Potential

332 Pages·1994·51.36 MB·English

by  David A. Cheresh (auth.)

Cellular Adhesion
Molecular Definition to
Therapeutic Potential
NEW HORIZONS IN THERAPEUTICS
SmithKline Beecham Pharmaceuticals U.S. Research Symposia Series
Series Editors: Brian W. Metcalfand George Poste
SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania
CELLULAR ADHESION: Molecular Definition to
Therapeutic Potential
J.
Edited by Brian W. Metcalf, Barbara Dalton, and George Poste
CELLULAR AND MOLECULAR ASPECTS OF INFLAMMATION
Edited by George Poste and Stanley T. Crooke
DOPAMINE RECEPTOR AGONISTS
Edited by George Poste and Stanley T. Crooke
MECHANISMS OF RECEPTOR REGULATION
Edited by George Poste and Stanley T. Crooke
NEW FRONTIERS IN THE STUDY OF GENE FUNCTIONS
Edited by George Poste and Stanley T. Crooke
NEW INSIGHTS INTO CELL AND MEMBRANE TRANSPORT
PROCESSES
Edited by George Poste and Stanley T. Crooke
PROTEIN DESIGN AND THE DEVELOPMENT OF NEW
THERAPEUTICS AND VACCINES
Edited byJerry B. Hook and George Poste
Cellular Adhesion
Molecular Definition to
Therapeutic Potential
Edited by
BR/AN W. METCALF
BARBARA 1. DALTON and
GEORGE POSTE
SmithKline Beecham Pharmaceuticals
Philadelphia, Pennsylvania
Technical Editor:
JUDY SCHATZ
SPRINGER SCIENCE+BUSINESS MEDIA, LLC
Library of Congress Cataloging-ln-Publication Data
Cellular adhesion : molecular definltion to therapeutlc potenial I
edited by Brian W. Metcalf, Barbara J. Dalton, and George Poste.
p. cm. -- (New horizons in therapeutics)
Includes bibliographical references and index.
ISBN 978·1-4613-6050-6 ISBN 978-1-4615-2466-3 (eBook)
DOI 10.1007/978-1-4615-2466-3
1. Cell adheSlon molecules--PhySiological effect. 2. Cell
adhesion molecules--Therapeutic use. 3. Cell adhesion.
1. Metcalf, Brian W. II. Dalton, Barbara J. III. Poste, George.
IV. Series.
[DNLM: 1. Cell Adhesion--physiology. 2. Cell Adhesion Molecules
-physiology. 3. Integrins--physiology. OH 623 C3936 1994]
OP552.C42C46 1994
591.87'6--dc20
DNLM/DLC
for Library of Congress 94-27164
CIP
ISBN 978-1-4613-6050-6
©1994 Springer Science+Business Media New York
Originally published by Plenum Press in 1994
Softcover reprint of the hardcover Ist edition 1994
AH rights reserved
No part of this book may be reproduced. stored in a retrieval system, or transmitted in any
form or by allY meallS. electronic, mechanical. photocopying. microfilming, recordillg. or
otherwise, without written permission from the Publisher
Contributors
Omid Abbassi, Department of Pediatrics, Baylor ColJege of Medicine,
Houston, Texas 77030
David H. Adams, The Experimental Immunology Branch, National Cancer
Institute, National Institutes of Health, Bethesda, Maryland 20892
Fadia Ali, Department of Medicinal Chemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania 19406
John Bean, Department of Medicinal Chemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania 19406
Donald R. Bertolini, Department of CelJular Biochemistry, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
James Callahan, Department of Medicinal Chemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania 19406
David A. Cheresh, Department of Immunology, The Scripps Research
Institute, La JolJa, California 92037
J. W Costerton, Department of Biological Sciences, University of Calgary,
Calgary, Alberta, Canada T2N IN4. Present address: Center for Biofilm
Engineering, Montana State University, Bozeman, Montana 59717
Kathryn L. Crossin, Department of Neurobiology, The Scripps Research
Institute, La JolJa, California 92037
Mark L. Entman, Section of Cardiovascular Sciences, Department of
Medicine, Baylor ColJege of Medicine, Houston, Texas 77030
v
VI Contributors
David V. Erbe, Department of Immunology, Genentech, Inc., South San
Francisco, California 94080
Lynne Flaherty, Department of Surgery, Harborview Medical Center,
University of Washington, Seattle, Washington 98104
John M. Harlan, Department of Medicine, Harborview Medical Center,
University of Washington, Seattle, Washington 98104
William Huffman, Department of Medicinal Chemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania 19406
David Jones, Department of Chemical Engineering, Rice University, Houston,
Texas 77030
Kenneth Kopple, Department of Physical and Structural Chemistry,
SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Paul F. Koster, Department of Cardiovascular Pharmacology, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Gilbert L. Kukielka, Section of Cardiovascular Sciences, The Methodist
Hospital, The DeBakey Heart Center, Department of Medicine, and Speros P.
Martel Laboratory of Leukocyte Biology, Department of Pediatrics, Texas
Children's Hospital, Baylor College of Medicine, Houston, Texas 77030
Laurence A. Lasky, Department of Immunology, Genentech, Inc., South San
Francisco, California 94080
D. Euan MacIntyre, Department of Cellular and Molecular Immunology,
Merck Research Laboratories, Rahway, New Jersey 07065
Rodger McEver, Department of Medicine and Biochemistry, University of
Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104
L. V. McIntire, Department of Chemical Engineering, Rice University,
Houston, Texas 77030
Michele Mariscalco, Department of Pediatrics, Baylor College of Medicine,
Houston, Texas 77030
George E. Mark, III, Department of Cellular and Molecular Biology, Merck
Research Laboratories, Rahway, New Jersey 07065
Contributors VII
Michael S. Mulligan, Department of Pathology, The University of Michigan,
Ann Arbor, Michigan 48109
Andrew J. Nichols, Department of Cardiovascular Pharmacology, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Eduardo A. Padlan, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, Bethesda, Maryland 20892
Catherine PeishojJ, Department of Physical and Structural Chemistry,
SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Leonard G. Presta, Department of Immunology, Genentech, Inc., South San
Francisco, California 94080
Anne L. Prieto, Department of Neurobiology, The Scripps Research Institute,
La Jolla, California 92037
Martin Ringwald, Max-Planck Institute for Immunobiology, Division of
Molecular Embryology, W-7800 Freiburg, Germany. Present address: The
Jackson Laboratory, Bar Harbor, Maine 04609
James M. Samanen, Department of Medicinal Chemistry, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Stephen Shaw, The Experimental Immunology Branch, National Cancer
Institute, National Institutes of Health, Bethesda, Maryland 20892
Melvin Silberklang, Department of Cellular and Molecular Biology, Merck
Research Laboratories, Rahway, New Jersey 07065
Irwin I. Singer, Department of Biochemical and Molecular Pathology, Merck
Research Laboratories, Rahway, New Jersey 07065
C. Wayne Smith, Departments of Pediatrics and Microbiology and
Immunology, Baylor College of Medicine, Houston, Texas 77030
K. B. Tan, Department of Cellular Biochemistry, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania 19406
Yoshiya Tanaka, The Experimental Immunology Branch, National Cancer
Institute, National Institutes of Health, Bethesda, Maryland 20892
VllI Contributors
Richard E. Valocik, Department of Cardiovascular Pharmacology, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Janice A. Vasko, Department of Cardiovascular Pharmacology, SmithKline
Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406
Peter A. Ward, Department of Pathology, The University of Michigan, Ann
Arbor, Michigan 48109
William I. Weis, Department of Biochemistry and Molecular Biophysics and
Howard Hughes Medical Institute, Columbia University, New York, New
York 10032. Present address: Department of Cell Biology, Stanford
University School of Medicine, Stanford, California 94305
Robert K. Winn, Department of Surgery and Physiology-Biophysics,
Harborview Medical Center, University of Washington, Seattle, Washington
98104
Samuel D. Wright, The Laboratory of Cellular Physiology and Immunology,
The Rockefeller University, New York, New York 10021
Preface to the Series
The unprecedented scope and pace ofdiscovery in modem biology and clinical
medicine present remarkable opportunities for the developmentofnew therapeu
tic modalities, many of which would have been unimaginable even a few years
ago. This situation reflects the unprecedented progress being made not only in
disciplines suchas pharmacology, physiology, organicchemistry, andbiochemis
try that have traditionally made important contributions to drug discovery, but
also in new disciplines such as molecular genetics, gene medicine, cell biology,
and immunology that are now ofsufficient maturity to further our understanding
ofthe pathogenesis ofdisease and the development ofnovel therapies. Contem
porary biomedical research, embracing the entire spectrum ofbiological organi
zation from the molecular level to whole body function, is on the thresholdofan
era in which biological processes, including disease, can be analyzed in increas
ingly precise and mechanistic terms. Thetransformationofbiology from a large
ly descriptive, phenomenological discipline to one in which the regulatory prin
ciples underlying biological organization can be understood and manipulated
with ever-increasing predictability brings an entirely new dimension to the study
ofdisease and the search for effective therapeutic modalities. In undergoing this
transformation into an increasingly mechanisticdiscipline, biology and medicine
are following thecourse already chartedby the sisterdisciplinesofchemistry and
physics, albeit still far behind.
The consequences of these changes for biomedical research are profound:
new concepts; new and increasingly powerful analytical techniques; new ad
vancesgeneratedata seeminglyever-rapidpace; an almost unmanageableglutof
information dispersed in an increasing number of books and journals; and the
task of integrating this information into a realistic experimental framework.
Nowhere is the challenge more pronounced than in the pharmaceutical industry.
Drug discovery and development have always required the successful coordina
tion of multiple scientific disciplines. The need to assimilate more and more
disciplines within the drug discovery process, the extraordinary pace of discov
ery in all disciplines, and the growing scientific andorganizationalcomplexityof
coordinating increasingly ultra-specialized and resource-intensive scientific
IX